home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410o.zip
/
M94A2789.TXT
< prev
next >
Wrap
Text File
|
1994-10-25
|
2KB
|
39 lines
Document 2789
DOCN M94A2789
TI Human recombinant erythropoietin (r-Hu EPO) for treatment of anemia in
HIV-infected children.
DT 9412
AU Caselli D; Maccabruni A; Fundaro C; Portelli E; De Santis U; Gabiano C;
Forni GL; Dept of Pediatrics, IRCCS Policl. San Matteo, Pavia, Italy.
SO Int Conf AIDS. 1994 Aug 7-12;10(1):224 (abstract no. PB0324). Unique
Identifier : AIDSLINE ICA10/94369786
AB BACKGROUND: Anemia is a frequent complication of HIV infection in
children, due both to HIV itself and, even more frequently, to
antiretroviral therapy. Treatment with r-Hu EPO was reported in HIV
infected adults, but data are not available for pediatric patients.
PATIENTS: 10 children (5 males, age 3 months-10 years, 9 vertically and
1 transfusion HIV infected) with symptomatic HIV infection were treated
for AZT related (8 pts) or HIV related (2 pts) anemia. One pt was also
beta thalassemic and one had cardiomyopathy. r-Hu EPO was used s.c. (n =
8) or e.v. (n = 2) at a dose range from 40 to 150 U/kg/3 times/week for
4 to 28 weeks (mean 16 weeks). RESULTS: Treatment was well tolerated, no
side effects were reported even in the cardiomyopathy patient. Good
response to EPO therapy was observed in 8/10 pts with mean Hb levels
increment of 2.35 gr/dl and mean Hct increment of 6.5%. Of the two pts
who apparently failed to respond, one was the thalassemic one, who
reduced transfusion requirement, and the other had been treated at low
dose (40U/kg) for only one month. CONCLUSION: Our preliminary results
suggest that EPO treatment may be effective for treatment of HIV or
AZT-related anemia in HIV infected children.
DE Anemia/CHEMICALLY INDUCED/COMPLICATIONS/*THERAPY Biological Response
Modifiers/*THERAPEUTIC USE Child Child, Preschool Drug Evaluation
Erythropoietin/*THERAPEUTIC USE Female Human HIV
Infections/*COMPLICATIONS/DRUG THERAPY Infant Male Myocardial
Diseases/COMPLICATIONS Recombinant Proteins/*THERAPEUTIC USE
Thalassemia/COMPLICATIONS Zidovudine/ADVERSE EFFECTS/THERAPEUTIC USE
MEETING ABSTRACT
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).